# Brain Trust Accelerator Fund

> Brain Trust Accelerator Fund is a VC fund in Burlingame backing Health Care and Pharmaceutical. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Burlingame, United States
- Total investments: 6
- Last investment: Aug 2024
- Lead investor: 17%
- Last updated: Aug 2026
- Website: http://www.braintrustvc.com

Brain Trust Accelerator Fund is a VC fund in Burlingame focused on Health Care and Pharmaceutical. The Brain Trust Accelerator Fund focuses on early stage investments that address the diagnosis and treatment of brain related diseases.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 50% |
| Pharmaceutical | 3 | 50% |
| Therapeutics | 2 | 33% |
| Apps | 1 | 17% |
| Beauty | 1 | 17% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 50% |
| Seed | 1 | 17% |
| Series A | 1 | 17% |
| Funding Round | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neuro Therapia | NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. | $12.3M | Series B | Aug 06, 2024 |  |
| MyAvana | MyAvana, formerly known as Madame You, provides hair care recommendation system, combining artificial intelligence and hair care experts to support and guide women with their hair care. It offers a hair analysis service to recommend the best hair products and styling techniques for your unique hair type and texture. |  |  | Jan 11, 2024 |  |
| MyAvana | MyAvana, formerly known as Madame You, provides hair care recommendation system, combining artificial intelligence and hair care experts to support and guide women with their hair care. It offers a hair analysis service to recommend the best hair products and styling techniques for your unique hair type and texture. |  | Seed | Jan 10, 2024 |  |
| Chase Therapeutics | Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company focused on the development of better treatments for brain disease. | $20M | Series B | Oct 20, 2021 |  |
| Neuro Therapia | NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. | $8.8M | Series A | Sep 22, 2020 |  |
| Satoris | Satoris develops tests for neurological diseases such as Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy. They're committed to developing and commercializing neurodiagnostic tests that yield the earliest, most accurate, and most clinically relevant diagnoses, so that healthcare costs can be reduced while patientcare becomes even more effective. | $5.2M | Series B | Mar 25, 2008 |  |

6 of 6 investments shown.

## Co-investors
- [Cleveland Clinic](https://shizune.co/investors/profile/cleveland-clinic) — VC Fund, 3 deals together
- [Alzheimer's Drug Discovery Foundation](https://shizune.co/investors/profile/alzheimers-drug-discovery-foundation) — VC Fund, 2 deals together
- [Dolby Family Ventures](https://shizune.co/investors/profile/dolby-family-ventures) — VC Fund, 2 deals together
- Prisma Ventures — VC Fund, 2 deals together
- China Link Capital — VC Fund, 1 deal together
- CRUINT — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Brain Trust Accelerator Fund invest in?

Brain Trust Accelerator Fund invests primarily in Health Care, Pharmaceutical and Therapeutics startups, most often at Series B and Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Brain Trust Accelerator Fund last invest?

The most recent investment recorded for Brain Trust Accelerator Fund closed in Aug 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co